AU2002308347A1 - Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides - Google Patents

Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides

Info

Publication number: AU2002308347A1
Authority: AU; Australia
Prior art keywords: tumours; treatment; immunotherapeutic combinations; gangliosides; overexpress
Prior art date: 2001-04-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

AU2002308347A

Other versions

AU2002308347B2 (en

Inventor

Mauro A Alfonso Fernandez

Adriana Carr Perez

Yildian Diaz Rodriguez

Luis Enrique Fernandez Molina

Alexis Perez Gonzalez

Rolando Perez Rodriguez

Adriana Maria Rojas Del Calvo

Ana Maria Vazquez Lopez

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Centro de Immunologia Molecular

Original Assignee

Centro de Immunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-06

Filing date

2002-04-08

Publication date

2003-04-10

2001-04-06 Priority claimed from CU2001008420010084A external-priority patent/CU23007A1/en

2002-04-08 Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular

2003-04-10 Publication of AU2002308347A1 publication Critical patent/AU2002308347A1/en

2006-09-14 Application granted granted Critical

2006-09-14 Publication of AU2002308347B2 publication Critical patent/AU2002308347B2/en

2022-04-08 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CU2001008420010084A CU23007A1 (en)	2001-04-06	2001-04-06	IMMUNOTHERAPEUTIC COMBINATIONS FOR THE TREATMENT IMMUNOTHERAPEUTIC COMBINATIONS FOR THE TREATMENT OF TUMORS THAT OVER-EXPRESS GANGLIOSIDES TO OF TUMORS THAT OVER-EXPRESS GANGLOSIDES
CU84/2001		2001-04-06
PCT/CU2002/000002 WO2002081661A2 (en)	2001-04-06	2002-04-08	Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides

Publications (2)

Publication Number	Publication Date
AU2002308347A1 true AU2002308347A1 (en)	2003-04-10
AU2002308347B2 AU2002308347B2 (en)	2006-09-14

Family

ID=40291118

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AU2002308347A Ceased AU2002308347B2 (en)	2001-04-06	2002-04-08	Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
AU2002308348A Ceased AU2002308348B2 (en)	2001-04-06	2002-04-08	Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
AU2007231687A Expired - Fee Related AU2007231687B2 (en)	2001-04-06	2007-10-26	Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AU2002308348A Ceased AU2002308348B2 (en)	2001-04-06	2002-04-08	Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
AU2007231687A Expired - Fee Related AU2007231687B2 (en)	2001-04-06	2007-10-26	Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors

Country Status (37)

Country	Link
US (3)	US20040253233A1 (en)
EP (3)	EP1411064B1 (en)
JP (2)	JP4366080B2 (en)
KR (3)	KR100946168B1 (en)
CN (3)	CN100349920C (en)
AR (2)	AR033123A1 (en)
AT (3)	ATE406386T1 (en)
AU (3)	AU2002308347B2 (en)
BG (2)	BG66293B1 (en)
BR (3)	BRPI0208675B1 (en)
CA (2)	CA2441845C (en)
CU (1)	CU23007A1 (en)
CZ (2)	CZ304424B6 (en)
DE (2)	DE60228561D1 (en)
DK (2)	DK1411064T3 (en)
EA (2)	EA006310B1 (en)
EC (2)	ECSP034788A (en)
ES (2)	ES2312610T3 (en)
HK (3)	HK1066818A1 (en)
HR (2)	HRP20030805B1 (en)
HU (2)	HU228106B1 (en)
IL (2)	IL158246A0 (en)
IS (2)	IS6965A (en)
MX (2)	MXPA03008739A (en)
MY (3)	MY137078A (en)
NO (2)	NO331533B1 (en)
NZ (2)	NZ528598A (en)
PE (1)	PE20020972A1 (en)
PL (2)	PL208109B1 (en)
PT (2)	PT1411064E (en)
SG (1)	SG161737A1 (en)
SI (2)	SI1411064T1 (en)
SK (2)	SK287914B6 (en)
UA (3)	UA75393C2 (en)
UY (2)	UY27242A1 (en)
WO (2)	WO2002081496A2 (en)
ZA (2)	ZA200307585B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7297336B2 (en) *	2003-09-12	2007-11-20	Baxter International Inc.	Factor IXa specific antibodies displaying factor VIIIa like activity
CA2593714C (en) *	2005-02-04	2013-09-10	Survac Aps	Survivin peptide vaccine
FI20055398A0 (en) *	2005-07-08	2005-07-08	Suomen Punainen Risti Veripalv	Method for evaluating cell populations
ES2679994T3 (en) *	2005-08-11	2018-09-03	Arpi Matossian-Rogers	Peptides related to TCR-V-BETA for the treatment and diagnosis of autoimmune disease
PT1915397E (en)	2005-08-19	2015-04-30	Univ Pennsylvania	Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
ITFI20060163A1 (en) *	2006-06-29	2006-09-28	Menarini Internat Operations Luxembourg Sa	PHARMACEUTICAL COMPOSITION CONTAINING A MONOCLONAL ANTI-IDIOTIC ANTI-CA-125 AND ALUMINUM ANTIBODY
TWI434855B (en) *	2006-11-21	2014-04-21	Hoffmann La Roche	Conjugate and its use as a standard in an immunoassay
EP2255787A4 (en) *	2008-02-22	2014-08-27	Katayama Chemical Ind Co Ltd	Synthetic glycolipid-containing liposomes
EP2166085A1 (en)	2008-07-16	2010-03-24	Suomen Punainen Risti Veripalvelu	Divalent modified cells
TWI516501B (en)	2008-09-12	2016-01-11	禮納特神經系統科學公司	Pcsk9 antagonists
CN104877026B (en)	2009-03-10	2019-10-25	比奥根Ma公司	Anti- BCMA antibody
RU2587621C2 (en) *	2009-04-01	2016-06-20	Дженентек, Инк.	ANTI-FcRH5 ANTIBODIES, IMMUNOCONJUGATES THEREOF AND METHODS FOR USE THEREOF
CU23736A1 (en) *	2009-05-04	2011-11-15	Centro Inmunologia Molecular	ANTIBODIES RECOGNIZING SULFATIDES AND SULFATED PROTEOGLYCANS AND THEIR USE
CA2780713A1 (en) *	2009-09-03	2011-03-10	Vancouver Biotech Ltd.	Monoclonal antibodies against gonadotropin-releasing hormone receptor
WO2012096994A2 (en) *	2011-01-10	2012-07-19	Emory University	Antibodies directed against influenza
CU24070B1 (en)	2011-12-27	2015-01-29	Ct De Inmunología Molecular	PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMORS EXPRESSING REGF AND GM3 N-GLYCOLLATED GANGLIOSIDS (NEUGCGM3)
EP2641916A1 (en) *	2012-03-23	2013-09-25	Centre National de la Recherche Scientifique (C.N.R.S)	Novel antibodies anti-sPLA2-IIA and uses thereof
NZ702269A (en)	2012-06-15	2017-07-28	Pfizer	Improved antagonist antibodies against gdf-8 and uses therefor
AR096687A1 (en)	2013-06-24	2016-01-27	Genentech Inc	ANTI-FCRH5 ANTIBODIES
SI3192812T1 (en)	2013-12-17	2020-10-30	Genentech, Inc.	Anti-cd3 antibodies and methods of use
CN112390887B (en) *	2014-04-10	2023-09-26	台湾浩鼎生技股份有限公司	Antibodies, hybridomas producing said antibodies, and uses thereof
TWI715587B (en)	2015-05-28	2021-01-11	美商安可美德藥物股份有限公司	Tigit-binding agents and uses thereof
US10323094B2 (en)	2015-06-16	2019-06-18	Genentech, Inc.	Humanized and affinity matured antibodies to FcRH5 and methods of use
WO2018017864A2 (en) *	2016-07-20	2018-01-25	Oncomed Pharmaceuticals, Inc.	Pvrig-binding agents and uses thereof
EP3548071A4 (en)	2016-11-30	2020-07-15	OncoMed Pharmaceuticals, Inc.	Methods for treatment of cancer comprising tigit-binding agents
CU20170173A7 (en) *	2017-12-27	2019-11-04	Ct Inmunologia Molecular	NANO-PARTICLES CONTAINING GM3 GANGLIOSIDE AS IMMUNOMODULATORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2754206B2 (en) *	1987-11-17	1998-05-20	メクト株式会社	Monoclonal antibody that recognizes α2 → 3 linkage
US6051225A (en) *	1988-10-19	2000-04-18	The Dow Chemical Company	Family of high affinity, modified antibodies for cancer treatment
ES2144440T3 (en) *	1992-08-18	2000-06-16	Centro Inmunologia Molecular	MONOCLONAL ANTIBODIES THAT RECOGNIZE THE RECEPTOR OF THE EPIDERMIC GROWTH FACTOR, CELLS AND METHODS FOR ITS PRODUCTION AND COMPOUNDS THAT CONTAIN THEM.
JPH07101999A (en) *	1993-10-06	1995-04-18	Hagiwara Yoshihide	Amino acid sequence of anti-idiotype antibody to anti-cancer human monoclonal antibody and dna base sequence coding for the same
ES2166770T3 (en) *	1993-12-09	2002-05-01	Centro Inmunologia Molecular	MONOCLONAL ANTIBODIES AGAINST GANGLIOSIDS AND THEIR USES IN THE SPECIFIC ACTIVE IMMUNOTHERAPY OF MALIGNOUS TUMORS.
US6063379A (en) *	1993-12-09	2000-05-16	Centro De Inmunologia Molecular	Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22702A1 (en) *	1997-10-21	2001-07-31	Centro Inmunologia Molecular	ANTI - IDIOTIPO MONOCLONAL ANTIBODIES, THEIR USE IN THE ACTIVE IMMUNOTHERAPY OF MALIGNUM TUMORS, HYBRIDOMA THAT PRODUCES THEM AND COMPOSITIONS THAT CONTAIN THEM
US6149921A (en) *	1993-12-29	2000-11-21	Centro De Inmunologia Molecular	Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (en) *	1993-12-29	1996-01-31	Centro Inmunologia Molecular	Vaccine composition for the development of an answer against gangliosides and glycolilades and its use for cancer treatment
CU22615A1 (en) *	1994-06-30	2000-02-10	Centro Inmunologia Molecular	PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
CU22731A1 (en) *	1998-02-05	2002-02-28	Centro Inmunologia Molecular	MONOCLONAL ANTIBODY THAT RECOGNIZES THE SYNLICAL OLIGOSACÁRIDO SYNALIC N´GLICOLILADO-GALACTOSA-GLUCOSA (NGCNEU-GAL-GLU) IN MALIGN TUMORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US7442776B2 (en) *	1999-10-08	2008-10-28	Young David S F	Cancerous disease modifying antibodies

2001
- 2001-04-06 CU CU2001008420010084A patent/CU23007A1/en unknown
2002
- 2002-04-05 MY MYPI20021228A patent/MY137078A/en unknown
- 2002-04-05 MY MYPI20021239A patent/MY157372A/en unknown
- 2002-04-05 AR ARP020101264A patent/AR033123A1/en not_active Application Discontinuation
- 2002-04-05 AR ARP020101263A patent/AR033122A1/en unknown
- 2002-04-05 UY UY27242A patent/UY27242A1/en not_active Application Discontinuation
- 2002-04-05 UY UY27243A patent/UY27243A1/en unknown
- 2002-04-05 MY MYPI20081190A patent/MY145703A/en unknown
- 2002-04-08 SG SG200506530-5A patent/SG161737A1/en unknown
- 2002-04-08 IL IL15824602A patent/IL158246A0/en unknown
- 2002-04-08 DE DE60228561T patent/DE60228561D1/en not_active Expired - Lifetime
- 2002-04-08 JP JP2002580025A patent/JP4366080B2/en not_active Expired - Fee Related
- 2002-04-08 CN CNB028086309A patent/CN100349920C/en not_active Expired - Fee Related
- 2002-04-08 SI SI200230660T patent/SI1411064T1/en unknown
- 2002-04-08 PL PL371937A patent/PL208109B1/en unknown
- 2002-04-08 KR KR1020037012969A patent/KR100946168B1/en not_active IP Right Cessation
- 2002-04-08 US US10/473,977 patent/US20040253233A1/en not_active Abandoned
- 2002-04-08 CA CA2441845A patent/CA2441845C/en not_active Expired - Fee Related
- 2002-04-08 HU HU0401355A patent/HU228106B1/en not_active IP Right Cessation
- 2002-04-08 PT PT02759752T patent/PT1411064E/en unknown
- 2002-04-08 EP EP02759752A patent/EP1411064B1/en not_active Expired - Lifetime
- 2002-04-08 AT AT02759751T patent/ATE406386T1/en active
- 2002-04-08 SI SI200230766T patent/SI1384726T1/en unknown
- 2002-04-08 PE PE2002000283A patent/PE20020972A1/en not_active Application Discontinuation
- 2002-04-08 DK DK02759752T patent/DK1411064T3/en active
- 2002-04-08 KR KR1020037012938A patent/KR100863509B1/en not_active IP Right Cessation
- 2002-04-08 AU AU2002308347A patent/AU2002308347B2/en not_active Ceased
- 2002-04-08 EA EA200301098A patent/EA006310B1/en not_active IP Right Cessation
- 2002-04-08 BR BRPI0208675-1A patent/BRPI0208675B1/en unknown
- 2002-04-08 WO PCT/CU2002/000003 patent/WO2002081496A2/en active Application Filing
- 2002-04-08 CN CN2007101021039A patent/CN101054417B/en not_active Expired - Fee Related
- 2002-04-08 SK SK1226-2003A patent/SK287914B6/en not_active IP Right Cessation
- 2002-04-08 CZ CZ2003-2668A patent/CZ304424B6/en not_active IP Right Cessation
- 2002-04-08 NZ NZ528598A patent/NZ528598A/en not_active IP Right Cessation
- 2002-04-08 BR BRPI0208676A patent/BR0208676B1/en not_active IP Right Cessation
- 2002-04-08 AT AT06076643T patent/ATE477279T1/en not_active IP Right Cessation
- 2002-04-08 EA EA200301097A patent/EA006936B1/en not_active IP Right Cessation
- 2002-04-08 AU AU2002308348A patent/AU2002308348B2/en not_active Ceased
- 2002-04-08 DK DK02759751T patent/DK1384726T3/en active
- 2002-04-08 NZ NZ528599A patent/NZ528599A/en not_active IP Right Cessation
- 2002-04-08 PL PL02371770A patent/PL371770A1/en not_active Application Discontinuation
- 2002-04-08 WO PCT/CU2002/000002 patent/WO2002081661A2/en active IP Right Grant
- 2002-04-08 US US10/473,978 patent/US20050069535A1/en not_active Abandoned
- 2002-04-08 CA CA2443372A patent/CA2443372C/en not_active Expired - Fee Related
- 2002-04-08 DE DE60223547T patent/DE60223547T2/en not_active Expired - Lifetime
- 2002-04-08 ES ES02759751T patent/ES2312610T3/en not_active Expired - Lifetime
- 2002-04-08 HU HU0401695A patent/HU228105B1/en not_active IP Right Cessation
- 2002-04-08 SK SK1216-2003A patent/SK287783B6/en not_active IP Right Cessation
- 2002-04-08 EP EP06076643A patent/EP1798243B1/en not_active Expired - Lifetime
- 2002-04-08 CZ CZ20032641A patent/CZ296276B6/en not_active IP Right Cessation
- 2002-04-08 PT PT02759751T patent/PT1384726E/en unknown
- 2002-04-08 MX MXPA03008739A patent/MXPA03008739A/en active IP Right Grant
- 2002-04-08 ES ES02759752T patent/ES2296986T3/en not_active Expired - Lifetime
- 2002-04-08 MX MXPA03008738A patent/MXPA03008738A/en not_active Application Discontinuation
- 2002-04-08 JP JP2002579482A patent/JP2004528033A/en active Pending
- 2002-04-08 EP EP02759751A patent/EP1384726B1/en not_active Expired - Lifetime
- 2002-04-08 CN CNB028084330A patent/CN1319991C/en not_active Expired - Fee Related
- 2002-04-08 AT AT02759752T patent/ATE378356T1/en active
- 2002-04-08 BR BR0208675-1A patent/BR0208675A/en not_active IP Right Cessation
- 2002-08-04 UA UA2003108989A patent/UA75393C2/en unknown
- 2002-08-04 UA UA2003108988A patent/UA76745C2/en unknown
2003
- 2003-09-23 IS IS6965A patent/IS6965A/en unknown
- 2003-09-23 IS IS6964A patent/IS2701B/en unknown
- 2003-09-29 ZA ZA200307585A patent/ZA200307585B/en unknown
- 2003-09-30 EC EC2003004788A patent/ECSP034788A/en unknown
- 2003-09-30 EC EC2003004787A patent/ECSP034787A/en unknown
- 2003-10-01 ZA ZA2003/07679A patent/ZA200307679B/en unknown
- 2003-10-02 IL IL158246A patent/IL158246A/en not_active IP Right Cessation
- 2003-10-03 BG BG108227A patent/BG66293B1/en unknown
- 2003-10-03 NO NO20034436A patent/NO331533B1/en not_active IP Right Cessation
- 2003-10-03 NO NO20034437A patent/NO20034437L/en not_active Application Discontinuation
- 2003-10-03 BG BG108228A patent/BG66304B1/en unknown
- 2003-10-06 HR HR20030805A patent/HRP20030805B1/en not_active IP Right Cessation
- 2003-10-06 HR HR20030806A patent/HRP20030806B1/en not_active IP Right Cessation
2004
- 2004-12-14 HK HK04109894A patent/HK1066818A1/xx not_active IP Right Cessation
2005
- 2005-04-01 HK HK05102752A patent/HK1070080A1/en not_active IP Right Cessation
- 2005-12-20 UA UAA200512270A patent/UA86768C2/en unknown
2007
- 2007-10-26 AU AU2007231687A patent/AU2007231687B2/en not_active Expired - Fee Related
- 2007-12-31 HK HK07114311.6A patent/HK1109160A1/en not_active IP Right Cessation
2008
- 2008-08-07 KR KR1020087019420A patent/KR100919617B1/en not_active IP Right Cessation
2009
- 2009-03-19 US US12/407,046 patent/US8758753B2/en not_active Expired - Fee Related

Publication	Publication Date	Title
AU2002308347A1 (en)	2003-04-10	Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
IL158246A0 (en)	2004-05-12	Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides
IL251270A0 (en)	2017-06-29	Cancer treatment
AU2002350235A1 (en)	2003-06-10	Combination bacteriolytic therapy for the treatment of tumors
IL164599A0 (en)	2005-12-18	Combination therapy for the treatment of cancer
HUP0400314A3 (en)	2006-02-28	Pharmaceutical combinations for the treatment of cancer
EP1599196A4 (en)	2006-05-31	Combination therapies for the treatment of cancer
AU2002334870B8 (en)	2003-04-22	Combinations for the treatment of immunoinflammatory disorders
HUP0500424A3 (en)	2008-04-28	Combination therapy for the treatment of cancer
IL164896A0 (en)	2005-12-18	Immunoconjugates for the treatment of tumours
AU2002221521A1 (en)	2002-08-22	Immunotherapeutic combinations for the treatment of tumors
AU2152102A (en)	2002-06-18	Immunotherapeutic combinations for the treatment of tumors
AU2002304883A1 (en)	2003-05-08	Device for the treatment of tumours
AU2002351382A1 (en)	2003-06-23	Combination cancer therapy
AU2002346661A1 (en)	2003-06-17	Photodynamic therapy for the treatment of epilepsy
ZA200408071B (en)	2005-10-18	Combination therapy for the treatment of cancer.
GB0115870D0 (en)	2001-08-22	Tumour therapy
AU2001273081A1 (en)	2003-03-03	Peptide combination for the treatment of cancer
ZA200306403B (en)	2004-04-29	Cancer treatment.
AU2002310189A1 (en)	2002-12-09	Tumor therapy